WEKO3
インデックスリンク
アイテム
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine
http://hdl.handle.net/2297/9917
http://hdl.handle.net/2297/9917f9921165-2155-446c-a036-86c5bea31e55
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-MABUCHI-H-609.pdf (545.4 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-10-03 | |||||
| タイトル | ||||||
| タイトル | Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Mabuchi, Hiroshi
× Mabuchi, Hiroshi× Sakai, Takeshi× Sakai, Yasuyuki× Yoshimura, Akira× Watanabe, Akira× Wakasugi, Takanobu× Koizumi, Junji× Takeda, Ryoyu |
|||||
| 書誌情報 |
New England Journal of Medicine 巻 308, 号 11, p. 609-613, 発行日 1983-01-01 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0028-4793 | |||||
| NCID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00755156 | |||||
| DOI | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.1056/nejm198303173081101 | |||||
| 出版者 | ||||||
| 出版者 | Massachusetts Medical Society | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | We studied the effects of the bile acid sequestrant cholestyramine, alone and in combination with the experimental agent compactin (ML-236B), a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on serum levels of lipoproteins in 10 heterozygous patients with familial hypercholesterolemia. After cholestyramine treatment alone for 2 to 16 months, serum total and low-density lipoprotein cholesterol decreased by 20 and 28 per cent, respectively. With the addition of compactin for 12 weeks there was a 39 per cent total decrease in serum cholesterol from the control value - from 356 ± 14 to 217 ± 10 mg per deciliter (9.27 ± 0.36 to 5.64 ± 0.26 nmol per liter [mean ± S.E.M.]; P < 0.001) - and a 53 per cent decrease in low-density lipoprotein cholesterol - from 263 ± 13 to 125 ± 10 mg per deciliter (6.84 ± 0.34 to 3.25 ± 0.26 nmol per liter; P < 0.001). High-density lipoprotein cholesterol, which had increased during cholestyramine treatment, remained at its higher level. No adverse effects were observed. If long-term safety can be demonstrated, the compactin-cholestyramine regimen may prove useful in heterozygous familial hypercholesterolemia. | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
